Stock Financial Ratios, Dividends, Split History

KPTI / Karyopharm Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)666.34
Enterprise Value ($M)597.34
Book Value ($M)95.53
Book Value / Share1.92
Price / Book5.15
NCAV ($M)82.47
NCAV / Share1.65
Price / NCAV11.38
Share Statistics
Common Stock Shares Outstanding 49,533,150
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 49,652,828
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.00
Return on Assets (ROA)-0.72
Return on Equity (ROE)-0.80
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio2.85
Income Statement (mra) ($M)
Sales Revenue Net0.00
Revenue From Grants0.00
License And Services Revenue1,605,000.00
Operating Income-130.54
Net Income-128.98
Earnings Per Share Basic And Diluted-2.81
Cash Flow Statement (mra) ($M)
Cash From Operations-73.72
Cash from Investing17.11
Cash from Financing-73.72
Identifiers and Descriptors
Central Index Key (CIK)1503802
Related CUSIPS
48576U906 48576U956

Split History

Stock splits are used by Karyopharm Therapeutics Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Karyopharm: Can Its Big Rally Continue?

2018-06-19 seekingalpha
The stock is up some 80% over the past six months thanks to a confluence of events including positive trial results. (1-0)

Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data

2018-06-18 seekingalpha
Selecta Biopharma (SELB) recently presented more data from Phase 2 clinical trial of its lead candidate SEL-212 (SVP-Rapamycin + pegsiticase) in chronic severe gout. In this trial 27 patients were inducted. 81% of the patient group had a clearly marked lower level of uric acid after three months of drug administration. This extended data is a definite improvement over data from earlier Phase 2 data in which 19 patients were evaluated and 75% of them had a clearly low level of uric acid after a similar 3-month duration. (182-0)

Stemline Therapeutics: Continued Upside In The Near Term

2018-06-13 seekingalpha
Expansion of SL-401 into additional indications and data for other pipeline candidates continue to provide significant optionality. (12-0)

Wedbush’s Monday ASCO Roundup

2018-06-05 247wallst
The 54th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result. Wedbush took a closer look at some of the companies in its coverage universe that presented on Monday and what the impact may be going forward. (33-3)

More Treatments for Multiple Myeloma Could Soon be Available for Patients

2018-05-30 biospace
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion. (5-2)

CUSIP: 48576U106